Test Price
2,800 AED✅ Home Collection Available
APP Gene Cerebral Amyloid Angiopathy (CAA) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary & Clinical Assurance
This advanced genetic test provides accurate diagnosis of hereditary cerebral amyloid angiopathy linked to the APP gene, with 99.9% diagnostic sensitivity and ISO 9001:2015 accredited processing.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA-licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next‑Generation Sequencing (NGS) assay analyses the entire APP gene to detect pathogenic variants linked to hereditary cerebral amyloid angiopathy (CAA) and familial Alzheimer’s disease. The test uses Illumina®‑based sequencing with Sanger confirmation to ensure >99.9% analytical sensitivity for all coding exons and flanking intronic regions.
| Feature | Our Test (NGS – CAA Panel) | Closest Alternative (Single‑Gene Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity for all coding exons ±20 bp of intron/exon boundaries | ~98% sensitivity; may miss large deletions or copy‑number variants |
| Methodology | Next‑Generation Sequencing (NGS) with Illumina® platform, verified by Sanger confirmation | Capillary Electrophoresis Sanger Sequencing |
| Turnaround Time | 3–4 Weeks (ISO‑certified cold‑chain handling) | 6–8 Weeks (often outsourced) |
| Regulatory Compliance | DHA/MOHAP Standard Nomenclature, UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. | Variable; may lack local legal safeguards |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Geneticist, I emphasise that an APP gene variant must be interpreted alongside clinical symptoms, neuroimaging, and a three‑generation pedigree. This test provides critical risk information; always discuss your results with a genetics‑trained specialist before making health decisions.”
— Lina Osama Zaki Quteineh, DHA Licence: 9294403
Clinical Advisory & Medication Warning
⚠️ Do not discontinue prescribed medication without consulting your doctor. Genetic results do not replace ongoing clinical care.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Patients unable to provide informed consent (legal guardian required); active severe neurological deterioration requiring immediate hospitalisation.
- Emergency Red Flags: Sudden severe headache, acute confusion, new‑onset seizures, or stroke‑like symptoms after receiving results.
- Genetic Counselling Mandate: Pre‑test genetic counselling and a three‑generation pedigree are required under UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability. Minors (< 18 years) must have parental consent.
Patient FAQ & Clinical Guidance
1. What exactly does the APP gene NGS test detect?
This NGS test comprehensively screens the entire APP gene for single‑nucleotide variants, small insertions/deletions, and copy‑number changes linked to hereditary cerebral amyloid angiopathy and early‑onset Alzheimer’s disease, achieving >99.9% analytical sensitivity.
2. How should I prepare for the test, and is it painful?
A simple blood draw or dried blood spot (FTA card) is collected by a DHA‑licensed phlebotomist during a home visit. No fasting is required, but you must complete a mandatory pre‑test genetic counselling session and provide a three‑generation family history. The procedure is minimally invasive.
3. What happens after I receive my results?
Your report is interpreted by a multidisciplinary team including a Consultant Medical Geneticist and a neurologist. You will receive a telephonic consultation to explain findings, assess familial risk, and coordinate a personalised management plan. Expert support continues throughout.
UAE Regulatory & Data Privacy Adherence
This test complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data are kept confidential and processed under strict security protocols. Patient consent and genetic counselling requirements follow Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | APP Gene (CAA) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Blood or Dried Blood Spot (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | I68.0 |
| LOINC Code | 81247-9 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians